Correction: Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rare WDR43::ALK structural deletion - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Case Report on Complete Response and Extended Survival with Alectinib in a NSCLC Patient Exhibiting a Rare WDR43::ALK Structural Deletion

  • By

  • Frontiers Production Office

  • September 11, 2026

Share

Original Source(s)

Correction: Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rare WDR43::ALK structural deletion

  • by Frontiers Production Office

  • September 11, 2026

Related Content

Cost-Effectiveness of Electronic Patient-Reported Outcome Measure Interventions in Cancer: Systematic Review and Parameter Extraction for Economic Modeling

Case Report: Treatment of an unresectable mucoepidermoid carcinoma with osimertinib

Clinician Counseling and Weight Loss Attempts Among Survivors of Obesity-Associated Cancers